Ulcerative Colitis

Researchers say depictions of inflammatory bowel disease (IBD). which includes ulcerative colitis, don't reflect the growing the incidence of IBD in older and nonwhite populations.

Previous studies on lipid levels and disease activity are inconsistent, and a causal relationship between lipid levels and IBD remains dubious.

Tremfya is an interleukin (IL)-23 and CD64-inhibiting monoclonal antibody. The FDA approved it in 2017 as a moderate to severe plaque psoriasis treatment. It has since been approved to treat psoriatic arthritis.

A study published in Nature Immunology focused on understanding the origins of stem-like T cells in ulcerative colitis patients. By analyzing colon tissue samples from human patients, researchers found a significant population of stem-like T cells in inflamed regions of the large intestine compared to healthy individuals.

In one key finding of the study, about half of the healthcare professionals listed bowel urgency as one of the top five symptoms that impact patients’ lives, however, only about a quarter of them ranked it as a top three symptom affecting treatment decisions.

In clinical guidelines, TNF inhibitors remain the preferred first-line advanced treatment for UC despite the emergence of new biologics approved for UC and Crohn’s disease. Head-to-head trials comparing the effectiveness of these treatments are scarce.

In a study recently published in BMJ Open Gastroenterology, researchers led by Pernille Dige Ovesen from the department of gastroenterology and hepatology in Copenhagen University Hospital investigated the effect of concomitant corticosteroid therapy on treatment outcomes in patients with UC initiating infliximab.

About 30% of people with Crohn’s disease, but on a population basis, it is rare event.

Home testing for fecal calprotectin, a commonly used marker in IBD diagnosis, and symptom quetionnaires might hasten the diagnosis of inflammatory bowel disease.

At 12 months, the rate of IBD-related surgeries for the monitored group was 1% versus 7% for the control group.

If the company' experimental agent is approved, it would join Humira (adalimumab), Rinvoq (upadacitinib) and Skyrizi (risankizumab) in AbbVie's portfolio.

Fecal microbiota transplant has not been approved for ulcerative colitis, but off-label use is a possiblity.

Insurance policy adherence to clinical guidelines ranged from 6% to 59%, according to findings reported in American Journal of Gastroenterology.

Elimination of insurance-mandated step therapy and allowing the Medicare beneficiaries to use copay assistance programs are among the changes the American Gastroenterological Association (AGA) wants to see.

Seres Therapeutics in Cambridge, Massachusetts, is one of the recipients.

Studies have shown that the use of oral corticosteroids in patients with UC is associated with higher rates of adverse effects and use of healthcare resources compared with biologics or immunosuppressants. However, there is little research focusing on the economic and clinical burden of chronic corticosteroid use among people living with UC.

Study authors hypothesized that factors such as depression, IBD medications, and stomach or rectal surgery may play a role in the increased risk of erectile dysfunction in patients with IBD.

A recent study found all women with a first-time perinatal depression diagnosis or who had been prescribed an antidepressant from the estimated date of conception to one year postpartum.

Janssen Biotech's Remicade (infliximab), an FDA-approved tumor necrosis factor inhibitor since 1998 for Crohn's disease, has gained additional approvals for managing ulcerative colitis and rheumatoid arthritis.

The American Gastroenterological Association recommendations do not take a stand for or against using probiotics for those with intermittent pouchitis.

Inflammatory bowel disease (IBD) clinical trials often involve participants getting numerous endoscopies. Cutting back on the number of endoscopies and using noninvasive tests instead was one of the ideas discussed for how to improve clinical trial design.

In an effort to reduce financial and other quality of life burdens for individuals living with ulcerative colitis, Hongliang Chen and his colleagues from the Department of Gastroenterology and Hepatology at four medical centers in northeast China sought to develop a routine blood-based tool for assessing the extent and severity of ulcerative colitis.

Ayble Health says it provides personalized nutrition and psychology services, Higher-risk patients will have expedited scheduling with Mayo Clinic multidisciplinary experts.

For patients with ulcerative colitis, levels of C-reactive protein, leukocytes, neutrophils, eosinophils, and platelets were significantly higher compared with controls three years before diagnosis.

Chronic systemic inflammation is believed to play a significant role in the association between inflammatory bowel disease and increased risk of arrhythmias.

Mirikizumab — now with the brand name — Omvoh is the first therapy that targets interleukin-23p19, which plays a role in inflammation. It has a list price of $9,593 per month for the IV formulation and $10,360 per subcutaneous administration.

Celltrion’s Zymfentra is subcutaneous version of infliximab.

Velsipity is the second S1P receptor modulator approved by the FDA to treat patients with moderate-to-severe ulcerative colitis. The wholesale acquisition cost is $6,164 for a 30-day supply.